5 Best Russell 2000 Stocks To Buy According To Hedge Funds

2. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Number of Hedge Fund Holders: 42

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a biopharmaceutical company focused on the discovery, clinical development, and commercialization of small molecule drugs primarily targeting intracellular signaling mechanisms in the central nervous system. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is one of the top Russell 2000 stocks to monitor. On February 22, the company reported a Q4 GAAP EPS of -$0.30, beating market consensus by $0.15. The revenue increased 50.2% year-over-year to $132 million, but fell short of Street estimates by $3.67 million. 

According to Insider Monkey’s fourth quarter database, 42 hedge funds were bullish on Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), compared to 37 funds in the last quarter. Kurt Von Emster’s VenBio Select Advisor is the biggest stakeholder of the company, with 2.25 million shares worth $161.5 million. 

TimesSquare Capital made the following comment about Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in its Q3 2022 investor letter:

“Slipping by -18% was Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), which develops small molecule treatments for neurological disorders. The company reported revenues that were better than expected, though earnings were lower. There was an acceleration of sales for Caplyta, a treatment for schizophrenia and bipolar depression. However, some investors appeared concerned that as Caplyta volumes increased to a higher level that the rate of growth would slow. We view the projected growth trajectory positively, as well as Caplyta’s potential for use in other indications, so we added to our position.”